Biomarkers to estimate long-term outcomes in patients with multiple sclerosis (MS) and to assign patients to individual treatment regimens are urgently needed.
W ith the amendment of the therapeutic armamentarium in multiple sclerosis (MS) by novel therapies, stratification of patients for individual therapies becomes an urgent need. Therefore, reliable prognostic markers for assigning patients to individual therapeutic regimens are essential. Cerebral and spinal magnetic resonance imaging (MRI) have long been the primary tool for the evaluation of paraclinical disease activity in MS. Whereas common MRI measures within the white matter reflect inflammatory disease activity, the value of currently used MRI variables to estimate future worsening disability is limited. 1 Imaging techniques for gray matter pathologic features were proposed to better reflect and estimate disability. 2 However, technical and methodologic issues prevent widespread use of this technique beyond experimental settings. 3 Retinal optical coherence tomography (OCT) is a fast and well-tolerated imaging technique that allows accurate and reproducible quantification of different retinal structures. 4 Optical coherence tomography might be a powerful technique for estimating inflammatory disease activity in MS 5, 6 that could also reflect responses to immunotherapeutic interventions in MS. 7 Recently, reduced peripapillary retinal nerve fiber layer (RNFL) thickness was linked to confirmed worsening of disability in patients with progressive and relapsing-remitting MS in a large multicenter cohort study. 8 In the present study, we investigated whether retinal OCT measures are associated with cellular and humoral inflammatory patterns in the cerebrospinal fluid (CSF) and whether OCT measures alone or in combination with CSF variables are associated with worsening disability in relapsing-remitting MS.
Methods

Study Design
In this prospective longitudinal cohort study, patients with relapsing-remitting MS aged 18 to 60 years and treated in the Department of Neurology, Klinikum Rechts der Isar, Munich, Germany, were included from April 15, 2013, through November 11, 2015. Relapsing-remitting MS was defined using the 2010 McDonald criteria. 9 Exclusion criteria were substantial eye disease, a refractive error of greater than 6 diopters, and neurologic comorbidities, which could affect disability. We excluded eyes with poor OCT quality 10 or with anamnestic or subclinical optic neuritis 11 before enrollment in the study. We followed STROBE statements for reporting cohort studies. The study was approved by the ethics commission of the Technische Universität München and followed the Declaration of Helsinki. 12 All patients provided written informed consent.
Two different longitudinal observational patient cohorts underwent analysis. Cohort 1 consisted of patients with very early relapsing-remitting MS, who had their first clinical relapse within the 3 months before baseline and underwent CSF analysis before inclusion in the study. Patients from cohort 2 did not undergo lumbar puncture before study enrollment and had longer disease durations (≥12 months) (eFigure 1 in the Supplement). At baseline, all patients underwent cerebral MRI, retinal OCT scanning, and clinical examination with recording of the Expanded Disability Status Scale (EDSS score) (range, 0-10, with higher scores indicating a higher grade of disability).
Patients from cohort 1 underwent lumbar puncture before baseline and prebaseline OCT scanning after lumbar puncture. Baseline visits took place at least 30 days after the last clinical relapse and last corticosteroid administration. Follow-up visits were scheduled depending on the clinical presentation. All patients underwent MRI and evaluation of the EDSS score at least once per year. The patients' diseasemodifying therapies (DMTs) were categorized into first-line DMT, including interferon beta-1a/b, glatiramer acetate, dimethyl fumarate, or teriflunomide, and second-line DMT, including natalizumab, fingolimod, alemtuzumab, or rituximab (according to the licensing of immunotherapies in Germany).
The primary clinical outcome variable was confirmed worsening of disability as measured by EDSS. Worsening EDSS was defined as an increase in the EDSS score of at least 1.0 points or at least 0.5 points in patients with an EDSS score of less than 5.5 or at least 5.5, respectively, and confirmed by a visit at least 3 months later. Additional outcome variables were annualized relapse rate, annualized increase in T2 lesion load, annualized number of gadolinium-enhancing (Gd+) lesions, and violation of the no evidence of disease activity 3 (NEDA-3) status, defined as the absence of relapses, confirmed EDSS worsening, Gd+ lesions, and new T2 lesions on cerebral MRI.
Imaging Studies
All MRI scans were acquired on a 3-T scanner (Achieva; Philips) as previously described. 13 Two blinded raters (C.W. and L.A.) manually counted numbers of lesions. For OCT images, we used a spectral domain OCT device (Spectralis; Heidelberg Engineering) as previously described. 7 In brief, evaluation of the peripapillary RNFL was performed using a 3.4-mm ring scan centered on the optic nerve head (automatic real time [ART], 100). The macular area underwent 61 vertical B-scans (scanning angle, 30°× 25°) focusing on the fovea centralis (ART, 13). We checked all examinations for sufficient quality using OSCAR-IB (obvious problems, poor signal strength, centration of scan, algorithm failure, retinal pathologic feature other
Key Points
Question Are retinal layer volumes as measured by optical coherence tomography associated with immunologic variables in the cerebrospinal fluid and with distinct aspects of disease activity in patients with relapsing-remitting multiples sclerosis?
Findings In this cohort study of 312 patients, atrophy of the ganglion cell layer was associated with increased intrathecal B-cell fractions and was a strong and independent risk factor for confirmed worsening of disability, whereas thickening of the inner nuclear layer correlated with enhanced brain activity at magnetic resonance imaging.
Meaning Retinal optical coherence tomography might be a convenient tool to estimate different disease activity patterns during multiple sclerosis and might support stratification of patients for different therapies.
than MS related, illumination, and beam placement) criteria.
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According to the OSCR-IB criteria, a signal strength greater than 15 dB was considered as sufficient for retinal segmentation and volume assessment. Every B-scan was segmented automatically into different layers using Eye Explorer software (version 6.0.9.0; Heidelberg Engineering). We checked segmentations manually and corrected in a blinded manner if necessary. Layer volumes were calculated by the software's segmentation algorithm (6-mm-diameter circle around the fovea).
CSF and Blood Analysis
We obtained CSF and blood samples before initiation of any immunomodulatory therapy. Samples were processed immediately after collection. Concentrations of albumin, IgG, IgM, and IgA were measured in cell-free CSF and serum by using a commercially available analyzer (BNProSpec; Siemens). For cellular analyses, fresh CSF and blood cells (after red blood cell lysis) were washed with 2% fetal calf serum and phosphatebuffered saline and directly processed on ice. Surface staining was performed using CD14-FITC, CD138-PE, CD19-ECD, CD56-APC, CD8-PE-Cy7 (all from Beckman Coulter), CD45-V450, CD4-PerCP, and CD3-APC-Cy7 (all from BD Bioscience) for 30 minutes at 4°C. Samples were analyzed directly after the staining procedure using an advanced digital processing analyzer (CyAn ADP; Beckman Coulter) and FlowJo software (version 10.1; FlowJoj, LLC). Gating strategies and analyzed cell populations are shown in eFigure 2 in the Supplement.
Statistical Analysis
For statistical analyses, we used R software (version 3. 
Results
Study Population
In total, 322 patients with relapsing-remitting MS were recruited for this study from the Department of Neurology, Klini- Both groups showed similar EDSS values and annualized relapse rates. Patients from cohort 1 tended to exhibit higher paraclinical disease activity as measured by the increase in T2 lesion load at brain MRI and tended to have higher rates of disability worsening during follow-up ( Table 1 ). The OCT measures at baseline were similar in both cohorts. In both groups, peripapillary RNFL, macular RNFL, and the common ganglion cell and inner plexiform layer (GCIPL) correlated positively with each other, whereas the total macular volume correlated positively with all retinal layers (eTable 1 in the Supplement). In both cohorts, GCIPL volume correlated positively with the inner nuclear layer (INL) (eTable 1 in the Supplement). In summary, our cohorts were representative of patients with MS and mild clinical affection. The fraction of patients with confirmed disability worsening was within the range of recently reported cohorts receiving treatment.
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Correlation of OCT Variables With Patterns of Inflammatory Cells in the CSF
The OCT analysis was performed a median of 23.5 days (IQR, 0-40 days) after lumbar puncture. Twenty of 72 patients in cohort 1 underwent OCT scanning on the day of the lumbar puncture and thus before corticosteroid therapy. Forty-nine of the remaining 52 patients received high-dose methylprednisolone therapy before OCT analysis. Forty-three of these patients underwent an additional OCT scan at least 30 days after corticosteroid pulse therapy. We observed no differences in retinal layer architecture between OCT measurements obtained during and 30 days after corticosteroid pulse therapy. 
Correlation of OCT Variables With Subsequent Disease Activity in Early MS
To test whether retinal layers were correlated with worsening of MS, we evaluated baseline retinal layer measurements for their associations with different variables of clinical and paraclinical disease activity in patients with early MS (cohort 1) during follow-up. As expected, INL volumes correlated positively with the increase in T2 lesion load and the number of Gd+ lesions during the 3-year follow-up ( Figure 2A ). Low peripapillary RNFL values were associated with high annualized numbers of new T2 lesions ( Figure 2A ). We noticed a weak negative correlation of GCIPL volumes with the annualized relapse rate ( Figure 2B ).
When further assessing clinical variables, we noticed that patients with worsening of EDSS scores had lower GCIPL volumes compared with patients with stable EDSS scores as a unique feature ( Table 2) . To further test the predictive value of OCT measures for disability worsening, we divided all patients into 2 groups according to the median of their retinal layer measurements. In this analysis, low GCIPL volumes at baseline were associated with an increased risk for confirmed worsening of EDSS scores during the subsequent 3 years. Patients with GCIPL volumes of 1.99 mm 3 or lower had a 6.4-fold (Harrell C, 0.752) increased risk for disease worsening compared with patients with higher GCIPL volumes ( Figure 2C ). peripapillary RNFL values (HR, 2.6; 95%, CI 0.9-7.5; P = .07; Harrell C, 0.721). When dividing the cohort into 3 tertiles, patients with the lowest peripapillary RNFL values (≤96 μm) were 4.1-fold more likely to develop disability progression than patients in the highest peripapillary RNFL tertile (>103 μm) (HR, 4.1; 95% CI, 1.1-15.9; P = .04; Harrell C, 0.72). Except for GCIPL, no other retinal layer correlated with worsening of MS ( Figure 2D ). Furthermore, patients with low GCIPL volumes (≤1.99 mm 3 ) had a 3.1-fold higher risk for violating NEDA-3 criteria than patients with high GCIPL volumes (Harrell C, 0.718; AUC, 0.65; sensitivity, 66.0%; specificity, 80.0%; PPV, 86.1%; NPV, 55.6%; accuracy, 75.4%) ( Figure 2E ). Thus, low GCIPL volumes represent an independent risk factor for confirmed disability worsening. Because we identified GCIPL thinning as a risk factor for disease worsening independently of CSF variables, we also checked the predictive value of GCIPL measures in a second cohort of patients with MS and longer disease durations (cohort 2). Again, peripapillary RNFL thickness and GCIPL volumes correlated negatively with the number of annualized new T2 lesions, and INL volumes correlated positively with the annualized increase in T2 lesion load and the annualized number of Gd+ lesions during follow-up ( Figure 3A) . Patients whose disease worsened revealed higher annualized relapse rates, more annualized Gd+ lesions, and a greater increase in T2 lesion load (eTable 3 in the Supplement). As in the cohort with early MS, patients with GCIPL volumes of 2.00 mm 3 or lower had a 2.4-fold increased risk for worsening of disease (Harrell 3 (high). E, Cumulative fraction of patients with ongoing disease activity (as measured by violation of the no evidence of disease activity 3 [NEDA-3] criteria) in patients stratified according to their GCIPL volume measurements at baseline. GCIPL values were divided into groups according to the median as described in part C. Kaplan-Meier analysis with robust multivariate Cox regression analysis corrected for the covariates age, sex, EDSS score at baseline, disease duration, and treatment group (C-E). HR indicates hazard ratio. C, 0.637; AUC, 0.61; sensitivity, 64.9%; specificity, 53.7%; PPV, 20.7%; NPV, 89.9%; accuracy, 55.0%) compared with patients with GCIPL values higher than 2.00 mm 3 ( Figure 3B ).
Again, neither stratification above or below the median INL value (HR, 0.8; 95% CI, 0.4-1.4; P = .39; Harrell C, 0.661) nor stratification above or below the median peripapillary RNFL value segregated with prospective confirmed disability worsening (HR, 1.4; 95% CI, 0.8-2.4; P = .27; Harrell C, 0.663). Unlike patients with early MS, low GCIPL volumes were not a risk factor for violating NEDA-3 criteria during the subsequent 3-year follow-up in cohort 2 patients (Harrell C, 0.658) ( Figure 3C ).
Discussion
In the present study, we show that retinal layers as measured by OCT are associated with distinct facets of intrathecal immunity and reflect different aspects of disease activity in MS. Low GCIPL volumes are associated with increased frequencies of intrathecal CD19 + B cells and higher rates of intra- 30 Our study now links GCIPL loss with B-cell immunity in the CSF. However, GCIPL thinning remained an independent risk factor for subsequent disease worsening when correcting for B-cell frequencies and CSF/serum IgG index. Thus, whether B-cell responses in the CSF and GCIPL atrophy are mechanistically linked needs to be tested in future studies. The predictive value of GCIPL atrophy for subsequent disease activity was different for both MS cohorts. The effect of GCIPL loss on EDSS worsening was higher in patients with early MS compared with patients with longer disease durations. In early MS stages, GCIPL might even be In a recent study, peripapillary RNFL atrophy has already been described as a risk factor for confirmed EDSS worsening in MS. 8 In that study, mainly older patients (40.6 years) with longer disease durations (6.5 years) have been investigated. With use of the top and bottom ranks of a tertile split of the peripapillary RNFL, the bottom peripapillary RNFL values in our study were associated with EDSS scores worsening.
Limitations
Our study has several limitations. First, only a small fraction of patients underwent OCT scanning on the day of the spinal tap. Thus, we cannot exclude an influence of corticosteroid therapy on retinal architecture. However, several patients underwent an additional OCT examination, and we did not see changes in the retinal architecture irrespective of whether the OCT scan was performed before or after corticosteroid therapy.
Furthermore, our patients are representative of early disease stages, and our results might not be able to be expanded to progressive disease. However, prognostic markers are particularly valuable in patients with MS at early disease stages to allot them to individual therapies when the therapeutic options are still diverse.
Conclusions
Our study shows that different retinal layers are associated with different patterns of intrathecal immunity and that those OCT measures might be associated with various aspects of disease activity patterns in MS. In particular, we identified GCIPL layer thinning as an independent risk factor for confirmed disability worsening. With a still increasing arsenal of DMTs in MS, OCT could help to identify patients who might benefit most from early therapeutic interventions with compounds that have the highest potential to halt disease worsening. Finally, associations of OCT variables with immune cell populations in the CSF might help to raise informed hypotheses on pathophysiologic links between the immune response in MS and retinal pathologic findings that will have to be tested in future studies. 
